1. Home
  2. MCGA vs NGEN Comparison

MCGA vs NGEN Comparison

Compare MCGA & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yorkville Acquisition Corp. Class A Ordinary Share

MCGA

Yorkville Acquisition Corp. Class A Ordinary Share

N/A

Current Price

$10.35

Market Cap

243.8M

Sector

Utilities

ML Signal

N/A

Logo NervGen Pharma Corp. Common stock

NGEN

NervGen Pharma Corp. Common stock

HOLD

Current Price

$2.07

Market Cap

200.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCGA
NGEN
Founded
2025
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Electric Utilities: Central
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
243.8M
200.0M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
MCGA
NGEN
Price
$10.35
$2.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
112.1K
614.7K
Earning Date
01-01-0001
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.09
$1.58
52 Week High
$10.83
$5.93

Technical Indicators

Market Signals
Indicator
MCGA
NGEN
Relative Strength Index (RSI) 65.94 51.00
Support Level $10.16 $2.07
Resistance Level N/A $2.32
Average True Range (ATR) 0.01 0.13
MACD -0.00 -0.02
Stochastic Oscillator 77.78 12.31

Price Performance

Historical Comparison
MCGA
NGEN

About MCGA Yorkville Acquisition Corp. Class A Ordinary Share

Yorkville Acquisition Corp is a blank check company.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: